Results 41 to 50 of about 30,099 (284)

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. [PDF]

open access: yes, 2014
Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.
Boger, M Sean   +11 more
core   +3 more sources

Probing chelation motifs in HIV integrase inhibitors [PDF]

open access: yesProceedings of the National Academy of Sciences, 2012
A series of HIV integrase (HIV-1 IN) inhibitors were synthesized to evaluate the role of the metal-binding group (MBG) in this class of metalloenzyme inhibitors. A total of 21 different raltegravir-chelator derivative (RCD) compounds were prepared that differed only in the nature of the MBG.
Arpita, Agrawal   +7 more
openaire   +2 more sources

Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids

open access: yesMolecules, 2015
HIV integrase, encoded at the 3′-end of the HIV pol gene, is essential for HIV replication. This enzyme catalyzes the incorporation of HIV DNA into human DNA, which represents the point of “no-return” in HIV infection.
Vasu Nair, Maurice Okello
doaj   +1 more source

Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors. [PDF]

open access: yes, 2011
Matrix metalloproteinases are zinc-containing enzymes capable of degrading all components of the extracellular matrix. Owing to their role in human disease, matrix metalloproteinase have been the subject of extensive study.
de Oliveira, César AF   +2 more
core   +1 more source

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure

open access: yesRetrovirology, 2009
In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A
Wang Bin   +5 more
doaj   +1 more source

Dynein Regulators Are Important for Ecotropic Murine Leukemia Virus Infection [PDF]

open access: yes, 2016
Indexación: Web of Science.During the early steps of infection, retroviruses must direct the movement of the viral genome into the nucleus to complete their replication cycle.
Arriagada, Gloria   +4 more
core   +1 more source

Resistance to inhibitors of the human immunodeficiency virus type 1 integration

open access: yesBrazilian Journal of Infectious Diseases
This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 ...
Daria J Hazuda
doaj   +1 more source

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation [PDF]

open access: yes, 2017
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus ...
Albert, Brice J   +8 more
core   +2 more sources

Integrase Strand Transfer Inhibitors in HIV Therapy [PDF]

open access: yesInfectious Diseases and Therapy, 2013
HIV drug resistance has been one of the major obstacles to HIV eradication and has contributed to the need for the constant development of new antiretroviral drugs over the past 25 years. With the recent approval of dolutegravir for human therapy by the U.S.
Mesplède, Thibault, Wainberg, Mark A.
openaire   +2 more sources

Screening of the NIH Clinical Collection for inhibitors of HIV-1 integrase activity

open access: yesSouth African Journal of Science, 2018
Drug repurposing offers a validated approach to reduce drug attrition within the drug discovery and development pipeline through the application of known drugs and drug candidates to treat new indications.
Shaakira Abrahams   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy